ReviewCurrent oncology (Toronto, Ont.)2019
Adjuvant therapy for stages II and III colon cancer: risk stratification, treatment duration, and future directions.
Review in Current oncology (Toronto, Ont.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Examining Colorectal Cancer Treatment Patterns and Outcomes in Asian American, Native Hawaiian, and Pacific Islander Patients, 2007-2020.Journal of racial and ethnic health disparities · 2025Article
- The expression of PRMT5 is associated with postoperative chemotherapeutic outcome in colon cancer.BMC cancer · 2025Article
- The role of adjuvant chemotherapy in rectal cancer: A nationwide cohort study from the Netherlands.Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland · 2025Article
- Ultrasound-Triggered Nanogel Boosts Chemotherapy and Immunomodulation in Colorectal Cancer.ACS applied materials & interfaces · 2025Article
- TLR4/MyD88 expression patterns and novel genetic variants: association with aggressive clinicopathological features in colorectal cancer.Frontiers in oncology · 2025Article
- Machine Learning Predicts Oxaliplatin Benefit in Early Colon Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024Article
- Identification of key modules and micro RNAs associated with colorectal cancer via a weighted gene co-expression network analysis and competing endogenous RNA network analysis.Journal of gastrointestinal oncology · 2023Article
- Stage III deficient mismatch repair colon patients get greater benefit from earlier starting oxaliplatin-based chemotherapy regimen.Scientific reports · 2023Article
- Review
- Open, Laparoscopic, and Robotic Approaches to Treat Colorectal Cancer: A Comprehensive Review of Literature.Cureus · 2023Review
- Expression of aquaporin 1, 3 and 5 in colorectal carcinoma: correlation with clinicopathological characteristics and prognosis.Pathology oncology research : POR · 2023Article
- Risk stratification for predicting postoperative recurrence/metastasis of colorectal cancer by grade of venous invasion coupled with histological subtype.BMC gastroenterology · 2022Article
- Protein Kinase Inhibitor-Mediated Immunoprophylactic and Immunotherapeutic Control of Colon Cancer.Frontiers in immunology · 2022Article
- Nanomedicines in the treatment of colon cancer: a focus on metallodrugs.Drug delivery and translational research · 2022Review
- Identification of colorectal cancer associated biomarkers: an integrated analysis of miRNA expression.Aging · 2021Article
- Exosomal Components and Modulators in Colorectal Cancer: Novel Diagnosis and Prognosis Biomarkers.Biomedicines · 2021Review
- Dual inhibition of TGFβ and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchymal phenotype.Medical oncology (Northwood, London, England) · 2021Article
- Review
- Adjuvant Chemotherapy for Stage II Colon Cancer.Cancers · 2020Review
- The Liquid Biopsy in the Management of Colorectal Cancer: An Overview.Biomedicines · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To date, the role of adjuvant systemic therapy in stages ii and iii colon cancer remains a topic of interest and debate. The objective of the present review was to assess the most recent data, specifically addressing methods of risk stratification, duration of therapy, and future directions. Methods: PubMed and medline were searched for literature pertinent to adjuvant chemotherapy in either stage ii or stage iii colorectal cancer. Summary: Locoregional disease, histopathology, age, laterality, and a number of other biologic and molecular markers appear to have a role in disease risk stratification. The duration of adjuvant therapy for stage iii disease can vary based on risk factors, but use of adjuvant therapy and duration of therapy in stage ii disease remain controversial. Future directions should include genomic assays and improved study design to provide concrete evidence about the duration of adjuvant folfox or capox and about other types of chemotherapy and immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.